Vistagen announces completion of last patient, last visit in phase 1 clinical trial of itruvone (ph10), an investigational pherine nasal spray for major depressive disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced that the last participant has completed the study protocol in its u.s. phase 1 clinical trial of itruvone (ph10), the company's investigational pherine nasal spray for the treatment of major depressive disorder (mdd).
VTGN Ratings Summary
VTGN Quant Ranking